The benefits of growth hormone therapy in patients with Turner syndrome, Noonan syndrome and children born small for gestational age.
This review will summarize the effects of growth hormone (GH) on height, body composition, bone and psychosocial parameters in children with Turner syndrome or Noonan syndrome and those born small for gestational age. The safety of GH treatment in children with these diagnoses is also reported. Despite the reported efficacy and safety of GH in these indications, however, not all children achieve their target height potential, due in some part to poor adherence to GH therapy regimens; indeed up to 50% of children are less than fully compliant with treatment. With this in mind the present and future administration of GH therapy is discussed with respect to advances being made in the presentation of GH for injection and advances in GH injection devices. It is hoped that such progress, aimed at making the administration of GH easier and less painful for the patient will improve treatment adherence and outcome benefits.
Novo Nordisk A/S, Copenhagen, Denmark. AMK@novonordisk.com
Anne-Marie
AM
Kappelgaard
Torben
T
Laursen
D006130:Growth Disorders / Q000188:drug therapy*; D019382:Human Growth Hormone / Q000627:therapeutic use*; D006801:Humans; D007231:Infant, Newborn; D007236:Infant, Small for Gestational Age; D009634:Noonan Syndrome / Q000188:drug therapy*; D014424:Turner Syndrome / Q000188:drug therapy*
D019382:Human Growth Hormone